siRNA and methods of manufacture

Details siRNA and methods of manufacture siRNA and methods of manufacture

2011-01-18

2011-01-18

Bowman, Amy (Department: 1635)

Organic compounds -- part of the class 532-570 series

Organic compounds

Carbohydrates or derivatives

C435S091100, C536S023100, C536S025300

Reexamination Certificate

active

07872118

ABSTRACT:
Double-stranded RNA of about 19 to about 25 nucleotides in length capable of regulating gene expression by RNA interference is provided. Such double-stranded RNA are particularly useful for treating disease or conditions associated with a target mRNA or gene. Methods of manufacture and methods of use of the double-stranded RNA are also provided.

REFERENCES:
patent: 4235871 (1980-11-01), Papahadjopoulos
patent: 4501728 (1985-02-01), Geho et al.
patent: 4837028 (1989-06-01), Allen
patent: 4920016 (1990-04-01), Allen et al.
patent: 5019369 (1991-05-01), Presant et al.
patent: 5139941 (1992-08-01), Muzyczka et al.
patent: 5252479 (1993-10-01), Srivastava
patent: 5624803 (1997-04-01), Noonberg et al.
patent: 5801156 (1998-09-01), Robinson et al.
patent: 5902598 (1999-05-01), Chen et al.
patent: 6015894 (2000-01-01), Bennett et al.
patent: 6020462 (2000-02-01), Semenza
patent: 6121000 (2000-09-01), Wright et al.
patent: 6177401 (2001-01-01), Ullrich et al.
patent: 6331313 (2001-12-01), Wong et al.
patent: 6355271 (2002-03-01), Bell et al.
patent: 6375972 (2002-04-01), Guo et al.
patent: 6506559 (2003-01-01), Fire et al.
patent: 7148342 (2006-12-01), Tolentino et al.
patent: 2002/0086356 (2002-07-01), Tuschl et al.
patent: 2002/0132788 (2002-09-01), Lewis et al.
patent: 2002/0162126 (2002-10-01), Beach et al.
patent: 2002/0173478 (2002-11-01), Gewirtz
patent: 2003/0138407 (2003-07-01), Lu et al.
patent: 2003/0153519 (2003-08-01), Kay et al.
patent: 2003/0216335 (2003-11-01), Lockridge et al.
patent: 2004/0018176 (2004-01-01), Tolentino et al.
patent: 2004/0096848 (2004-05-01), Thrue et al.
patent: 2004/0115640 (2004-06-01), Myers et al.
patent: 2004/0180357 (2004-09-01), Reich et al.
patent: 2004/0220129 (2004-11-01), Reich et al.
patent: 2004/0248174 (2004-12-01), Reich et al.
patent: 2004/0259247 (2004-12-01), Tuschl et al.
patent: 2005/0048529 (2005-03-01), McSwiggen
patent: 2005/0159380 (2005-07-01), Guerciolini et al.
patent: 2005/0187174 (2005-08-01), Richards et al.
patent: 2005/0197315 (2005-09-01), Taira et al.
patent: 2005/0246794 (2005-11-01), Khvorova et al.
patent: 2007/0178068 (2007-08-01), Reich et al.
patent: 2359180 (2000-08-01), None
patent: 1144623 (2002-08-01), None
patent: WO 93/24641 (1993-12-01), None
patent: WO 94/13788 (1994-06-01), None
patent: WO 01/57206 (2001-08-01), None
patent: WO 01/75164 (2001-10-01), None
patent: WO 02/44321 (2002-06-01), None
patent: WO 02/096927 (2002-12-01), None
patent: WO 03/066805 (2003-08-01), None
patent: WO 03/070910 (2003-08-01), None
patent: WO 03/087367 (2003-10-01), None
patent: WO 03/087368 (2003-10-01), None
patent: WO 03/099298 (2003-12-01), None
patent: WO 2004/009769 (2004-01-01), None
patent: WO 2004/013310 (2004-02-01), None
patent: WO 2004/065546 (2004-08-01), None
patent: WO 2004/094606 (2004-11-01), None
patent: WO 2005/028649 (2005-03-01), None
Banan et al., The Ins and Outs of RNAi in Mammalian Cells, 2004, Current Pharmaceutical Biotechnology, 5, pp. 441-450.
Bullard et al., Direct comparison of nick-joining activity of the nucleic acid ligases from bacteriophage T4, 2006, Biochem. Soc. 398:135-144.
Database retrieved from EBI accession No. GSN:ADY90830, [Online] Jun. 16, 2005, VEGF siRNA SEQ ID No. 3867, XP002468090.
Database retrieved from EBI accession No. GSN:ADY90830, [Online] Jun. 16, 2005, VEGF siRNA SEQ ID No. 3868, XP002468091.
Nandakumar et al., RNA Substrate Specificity and Structure-guided Mutational Analysis of Bacteriophage T4 RNA Ligase 2, 2004, J. Biol. Chem. 279(30):31337-31347.
Reich et al., Small interfering RNA (siRNA) targeting VEGF effectively inhibits ocular neovascularization in a mouse model, 2003, Molecular Vision 9:210-216.
Kurschat et al., Optimizing splinted ligation of highly structured small RNAs, 2005, Cold Spring Harbor Laboratory Press, 2005, pp. 1909-1914.
Harborth et al., Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing, 2003, Antisense and Nucl. Acid Drug Dev. 13:83-105.
Elbashir et al., Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate, 2001, The EMBO J. 20(23):6877-6888.
Dorsett et al., siRNAs: Applications in Functional Genomics and Potential as Therepeutics, 2004, Nature 3(4):318-329.
Manoharan, RNA interference and chemically modified small interfering RNAs, 2004, Curr. Opin. Chem. Biol. 8:570-579.
Bustin, Absolute Quantification of mRNA using real-time reverse transcription polymerase chain reaction assays, 2000, J. Mol. Endocrinol. 25(2):169-193.
Tuschl et al., The siRNA User Guide, May 6, 2004, www.mpibpc.gwdg.de/abteilungen/100/105/sirna.html.
Tuschl, Expanding small RNA interference, 2002, Nat. Biotechnol. 20:446-448.
Brummelkamp et al., A System for Stable Expression of Short Interfering RNAs in Mammalian Cells, 2002, Science 296:550-553.
Miyagishi et al., U6 promoter-driven siRNAs with four uridine 3′ overhangs efficiently suppress targeted gene expression in mammalian cells, 2002, Nat. Biotechnol. 19:497-500.
Paddison et al., Short hairpin RNAs (siRNAs) induce sequence-specific silencing in mammalian cells, 2002, Genes Dev. 16:948-958.
Lee et al., Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells, 2002, Nat. Biotechnol. 19:500-505.
Paul et al., Effective expression of small interfering RNA in human cells, 2002, Nat. Biotechnol. 20:505-508.
Dornburg, Reticuloendotheliosis viruses and derived vectors, 1995, Gene Therap. 2:301-310.
Eglitis et al., Retroviral Vectors for Introduction of Genes into Mammalian Cells, 1988, Biotechniques 6(7):608-614.
Miller, Retrovirus Packaging Cells, 1990, Hum. Gene Therap. 1:5-14.
Anderson, Human Gene Therapy, 1998, Nature 392:25-30.
Xia et al., siRNA-mediated gene silencing in vitro and in vivo, 2002, Nat. Biotech. 20:1006-1010.
Samulski et al., A Recombinant Plasmid from Which an Infectious Adeno-Associated Virus Genome Can Be Excised In Vitro and Its Use to Study Viral Replication, 1987, J. Virol. 61(10):3096-3101.
Fisher et al., Transduction with Recombinant Adeno-Associated Virus for Gene Therapy is Limited by Leading-Strand Synthesis, 1996, J. Virol. 70(1):520-532.
Samulski et al., Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression, 1989, J. Virol. 63(9):3822-3828.
Szoka, JR et al., Comparative Properties and Methods of Preparation of Lipid Vesicles (Liposomes), 1980, Ann. Rev. Biophys. Bioeng. 9:467-508.
Gabizon et al., Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors, 1988, P.N.A.S. USA 85:6949-6953.
Acheampong et al., Distribution of Brimonidine into Anterior and Posterior Tissues of Monkey, Rabbit, and Rat Eyes, 2002, Drug Metabol. and Disposition 30(4):421-429.
Bennett et al., Humoral response after administration of E1-deleted adenoviruses: immune privilege of the subretinal space, 1996, Hum. Gene Ther. 7:1763-1769 (Abstract).
Ambati et al., Transscleral drug delivery to the retina and choroid, 2002, Progress in Retinal and Eye Res. 21:145-151.
Remington's Pharmaceutical Sciences, 17thed. Mack Publishing Co., Easton, PA, 1985.
Fire et al., Potent and specific genetic interference by double-stranded RNA inCaenorhabditiselegans, 1998, Nature 391:806-811.
Elbashir et al., RNA interference is mediated by 21-and 22-nucleotide RNAs, 2001, Genes Dev. 15:188-200.
Elbashir et al., Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells, 2001, Nature 411:494-498.
McCaffrey et al., RNA interference in adult mice, 2002, Nature 418:38-39.
Novina et al., siRNA-directed inhibition of HIV-1 infection, 2002, Nat. Med. 8(7):681-686.
Belletti et al., Modulation of in vivo growth of thyroid tumor-derived cell lines by sense and antisense vascular endothelial growth factor gene, 1999, Oncogene 18:4860-4869.
Roberts et al., Efficient expression of ribozyme and reduction of stromelysin mRNA in cultured cells and tissue from rabbit knee via Adeno-associated Virus (AAV), 1999, Gene Therapy and Molecular Biology 4:45-58.
Rub

Affiliated with

Also associated with

Rating

siRNA and methods of manufacture does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with siRNA and methods of manufacture, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and siRNA and methods of manufacture will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2669922